This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-09-1823v1 69/19/7612    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Wang, X. Articles by Hoffman, R. PubMed PubMed Citation Articles by Wang, X. Articles by Hoffman, R.

Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34⁺ Cells by Treatment with Chromatin-Modifying Agents

Division of Hematology/Oncology, Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, New York

Requests for reprints: Ronald Hoffman, Division of Hematology/Oncology, Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1079, New York, NY 10029. Phone: 212-241-2297; Fax: 212-876-5276; E-mail: ronald.hoffman{at}mssm.edu.

Key Words: CD34⁺ cells • PMF • CXCR4 • homing • chromatin modifying agents

The abnormal trafficking of CD34⁺ cells is a unique characteristic of primary myelofibrosis (PMF). We have further studied the behavior of PMF CD34⁺ cells by examining their homing to the marrow and the spleens of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Following the infusion of PMF and normal granulocyte colony-stimulating factor–mobilized peripheral blood (mPB) CD34⁺ cells into NOD/SCID mice, reduced numbers of PMF CD34⁺ cells and granulocyte-macrophage colony-forming unit (CFU-GM) compared with mPB were detected in the marrow of these mice, whereas similar numbers of PMF and mPB CD34⁺ cells and CFU-GM homed to their spleens. The abnormal homing of PMF CD34⁺ cells was associated with reduced expression of CXCR4, but was not related to the presence of JAK2V617F. The sequential treatment of PMF CD34⁺ cells with the chromatin-modifying agents 5-aza-2'-deoxycytidine (5azaD) and trichostatin A (TSA), but not treatment with small molecule inhibitors of JAK2, resulted in the generation of increased numbers of CD34⁺CXCR4⁺ cells, which was accompanied by enhanced homing of PMF CD34⁺ cells to the marrow but not the spleens of NOD/SCID mice. Following 5azaD/TSA treatment, JAK2V617F-negative PMF hematopoietic progenitor cells preferentially homed to the marrow but not the spleens of recipient mice. Our data suggest that PMF CD34⁺ cells are characterized by a reduced ability to home to the marrow but not the spleens of NOD/SCID mice and that this homing defect can be corrected by sequential treatment with chromatin-modifying agents. [Cancer Res 2009;69(19):7612–8]